ARTICLE | Emerging Company Profile
EpiBiologics tapping two lysosomal degradation mechanisms with $50M
The UCSF spinout is degrading membrane-bound and extracellular targets via bispecific antibody constructs it believes have a manufacturing advantage
March 23, 2023 1:02 AM UTC
With two bispecific antibody-based strategies for sending membrane and extracellular proteins to the lysosome, EpiBiologics Inc. aims to develop tissue-specific targeted degraders for a range of indications, and believes its modality has manufacturing advantages over competing approaches.
EpiBiologics emerged from stealth Wednesday with a $50 million series A round co-led by Mubadala Capital and Polaris Partners, and exclusive licenses to two lysosomal degradation platforms developed in the University of California San Francisco lab of Jim Wells. Vivo Capital and GV also participated in the round...